Logo image
Back
Time trends for HIV-1 antiretroviral resistance among antiretroviral-experienced and naive pregnant women in New York City during 1991 to early 2001
Journal article   Open access   Peer reviewed

Time trends for HIV-1 antiretroviral resistance among antiretroviral-experienced and naive pregnant women in New York City during 1991 to early 2001

Seth L Welles, Greta R Bauer, Philip S LaRussa, Robert C Colgrove and Jane Pitt
Journal of acquired immune deficiency syndromes (1999), v 44(3), pp 329-335
01 Mar 2007
DOI: https://doi.org/10.1097/QAI.0b013e31802f1296
PMID: 17179768
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1097/qai.0b013e31802f1296View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze),  Open

Abstract

Anti-HIV Agents - pharmacology Pregnancy Complications, Infectious - virology HIV-1 - drug effects HIV Infections - virology Humans Reverse Transcriptase Inhibitors - pharmacology HIV-1 - genetics HIV Protease Inhibitors - pharmacology New York City Pregnancy Drug Resistance, Viral - genetics RNA, Viral - genetics HIV-1 - isolation & purification Adult Female Mutation
Time trends in the prevalence of drug resistance to antiretroviral therapy (ART) in pregnant women have not been studied. Treatment and prophylactic efficacy could be compromised by drug-resistant HIV strains. We conducted a repeated cross-sectional study of antiretroviral resistance mutations to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) and of major mutations to protease inhibitors (PIs) in virus isolates from 300 HIV-infected pregnant women in New York City from 1991 to early 2001. The overall prevalence of mutations for NRTIs from 1991 to early 2001 was higher for ART-experienced (25.6% [95% confidence interval (CI): 19.1% to 32.1%]) than ART-naive (8.6% [95% CI: 3.7% to 13.4%]) mothers (P < 0.002). For NNRTIs, the overall prevalence of mutations was somewhat higher among ART-experienced (5.8% [95% CI: 2.3% to 9.3%]) versus ART-naive (1.6% [95% CI: 0% to 3.7%]) women (P = 0.06), and increased over time for ART-naive women (0%-7.4%; P = 0.03) and ART-experienced women (0%-19.4%; P = 0.0002). The prevalence of PI-associated mutations was also higher overall among ART-experienced mothers (5.8% [95% CI: 2.3% to 9.3%] vs. 1.6% [95% CI: 0% to 3.7%]; P = 0.06), with increases over time seen for ART-naive women (0%-7.4%; P = 0.03) and ART-experienced women (0%-16.1%; P = 0.0008). The increasing prevalence of drug resistance in pregnant women, including those who are drug-naive, underscores the necessity for resistance testing to guide treatment to achieve suppression of the mother's virus.

Metrics

10 Record Views
13 citations in Web of Science
14 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Immunology
Infectious Diseases
Logo image